Teva launches generic ACTOplus met to improve glucose control in adults with type 2 diabetes

Download PDF Copy

Aug 18 2012

NewsGuard 100/100 Score

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of an authorized generic of ACTOplus met® (pioglitazone/metformin tablets)15 mg/500 mg, 15 mg/850 mg.

ACTOplus met® is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOplus met® had annual sales of approximately $413 million in the United States, based on IMS sales data as of June 30, 2012.

Source:

Teva Pharmaceutical Industries Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Tags: Biotechnology, Blood, Blood Sugar, Diabetes, Diet, Endocrinology, Exercise, Generic Drug, Glucose, Medicaid, Medicare, Metformin, Oncology, Pain, Pharmaceuticals, Pioglitazone, Protonix, Respiratory, Type 1 Diabetes, Type 2 Diabetes, Type I Diabetes

Comments (0)

Download PDF Copy

Suggested Reading

Diabetes medication shows promise in reducing alcohol use

Diabetes medication shows promise in reducing alcohol use

Rare variant analysis reveals genetic spectrum of monogenic diabetes genes

Rare variant analysis reveals genetic spectrum of monogenic diabetes genes

SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients

SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients

Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options

Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options

Digital health technologies play a transformative role in diabetes management and prevention

Digital health technologies play a transformative role in diabetes management and prevention

Global diabetes cases exceed 800 million highlighting urgent need for action

Global diabetes cases exceed 800 million highlighting urgent need for action

Spermidine regulates RIPK1 to combat diabetes and vascular damage

Spermidine regulates RIPK1 to combat diabetes and vascular damage

Diabetes rates skyrocket globally with millions left untreated

Diabetes rates skyrocket globally with millions left untreated

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Intensive blood pressure treatment reduces cardiovascular risk in people with Type 2 diabetes